Response assessment criteria for brain metastases: proposal from the RANO group. - Wikidata - wikimedia - TriplyDB

Response assessment criteria for brain metastases: proposal from the RANO group.

Response assessment criteria for brain metastases: proposal from the RANO group.

http://www.wikidata.org/entity/Q30969912

about

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer High-resolution whole-brain DCE-MRI using constrained reconstruction: Prospective clinical evaluation in brain tumor patients [Melanoma brain metastases : Treatment options].Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.An Update on the Approach to the Imaging of Brain Tumors.Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?Prognostic Value of MR Imaging Texture Analysis in Brain Non-Small Cell Lung Cancer Oligo-Metastases Undergoing Stereotactic Irradiation.Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases Retrospective Analysis of Cerebrospinal Fluid Profiles in 228 Patients with Leptomeningeal Carcinomatosis : Differences According to the Sampling Site, Symptoms, and Systemic Factors Segmentation of peritumoral oedema offers a valuable radiological feature of cerebral metastasis.5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression.Radiosurgery for brainstem metastases with and without whole brain radiotherapy: clinical series and literature review.The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases.First follow-up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases.Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.Irradiation and immunotherapy: From concept to the clinic.RECIST - learning from the past to build the future.Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.Melanoma central nervous system metastases: current approaches, challenges, and opportunities.RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.Assessment of Brain Tumor Response: RANO and Its Offspring.Updates in the management of brain metastases.Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.The Treatment of Melanoma Brain Metastases.Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans.Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues.Immune Checkpoint Inhibitors for Brain Metastases.Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.Activity of T-DM1 in Her2-positive breast cancer brain metastases.Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective.PET imaging in glioma: is it time for mainstream practice?Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.Response Assessment in Neuro-Oncology Clinical Trials.The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.Impact of CyberKnife Radiosurgery on Overall Survival and Various Parameters of Patients with 1-3 versus ≥ 4 Brain Metastases.T cell densities in brain metastases are associated with patient survival times and diffusion tensor MRI changes.Identifying candidates for gamma knife radiosurgery among elderly patients with brain metastases.Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy.

P2860

Q26738985-84DA0021-0EDA-42A0-9142-008DE7A492F8 Q28600963-300253BC-B8A5-4B45-877A-3149EFC22A25 Q31098294-FB791FAB-E707-4C13-A106-E7FBBBA01D53 Q31158877-47FF954B-E5A5-4B8C-B7C2-27B034F7F09D Q36374577-D55C7396-0CA9-4692-A98F-E215111D5543 Q36516472-FD5F6B72-C603-4F6F-B8DE-CE42308477C7 Q36924250-5848A257-6CF1-4FB0-86AD-3AF2C637DE25 Q37350784-B10A8F2C-7205-45F6-89C9-00A73029D3F8 Q37409891-7E0D5EAF-755D-471A-A2EB-9BAA3EEA5CD3 Q37600899-7C2631CC-DF31-4568-8147-3D131F6C8218 Q37687070-F6326C6E-C105-48E4-898B-27C25B456CA7 Q37709924-986DAD38-10ED-4BBE-8D93-4718F72F7050 Q38289478-C55F7C0E-B29A-48E9-97ED-08B7F55E1A09 Q38641298-D154108F-5F1D-4C29-88D3-688AEF7EEBE7 Q38726649-4DF72182-AADC-47C6-ADB5-F262262E21F0 Q38737416-1DE423CA-686F-42DF-A532-BFCC7AA71E10 Q38749802-14F0C345-5964-46AC-8ADF-8CDB43E88FDE Q38780372-C77590B0-7E21-4219-AC07-B0D0DFBB9E86 Q38803916-9B119BAB-D624-4A3B-9E83-A4DA90649155 Q38807942-41A47E2F-7293-4EF9-8143-DECC7CCD228C Q38847450-5D27B4E0-69B2-45DF-838E-B16CBF0CC3F2 Q38855020-CD828401-B4EB-4E57-A4CC-896081CDBEA8 Q38887451-2EB9124A-C611-4CC0-A534-EA055E7DD7E8 Q38918333-D8CBACBF-3B33-45F0-A6C5-5C112C567507 Q39002330-09DD6514-E53F-4A34-9276-C5C059E2F521 Q39181712-54D72453-58EF-4D4F-BCD6-DB04B9132E70 Q39222410-7B8B2F96-514F-4120-9F11-21196ECAD27C Q39247421-118076F5-328F-4D2D-9BA7-3C1513F2B1FC Q39775271-4E19AE93-1C51-4D86-9940-5ED44FB527A0 Q40333907-7D644865-9BB9-4016-BA57-BCFEC55A9310 Q41455800-A122C113-6595-4D82-B4B8-2B4B34129107 Q41594601-243001DB-5F21-4733-8B34-9C7326FE9284 Q42332774-4C047DE2-A0E6-4A2F-8BD1-C7D9408A9396 Q42547688-17F1C6AA-0A29-4A9B-A45F-96B4B13ACD67 Q45945655-310A3B18-60D3-46D3-A072-C7DFFB02E364 Q46085094-B8177C61-CC02-4B40-8E7E-6DDBF95DF438 Q47133975-802FA780-B332-4DD7-A8DB-FF1438621C57 Q47322246-66ED2380-845E-4038-B6E1-4109C0F8C6A7 Q47554462-DE21D045-1CA9-4ABA-A3B6-44A2247C69A6 Q47768004-84EA3016-F1F8-4DE9-AD99-8B867DBDAE7F

P2860

Response assessment criteria for brain metastases: proposal from the RANO group.

http://www.wikidata.org/entity/Q30969912

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Response assessment criteria for brain metastases: proposal from the RANO group.

@ast

Response assessment criteria for brain metastases: proposal from the RANO group.

@en

type

label

Response assessment criteria for brain metastases: proposal from the RANO group.

@ast

Response assessment criteria for brain metastases: proposal from the RANO group.

@en

prefLabel

Response assessment criteria for brain metastases: proposal from the RANO group.

@ast

Response assessment criteria for brain metastases: proposal from the RANO group.

@en

P1433

Q30969912-5F5DDAC6-1675-414B-B6C3-EDBB5095ED7D

P1476

Q30969912-36FD7F39-7242-48F0-9A5E-13082278EF20

P2093

Q30969912-1B2BE402-1C56-48B2-B3D5-E0A5632CC481

Q30969912-1B3B4B21-6B56-4726-91CB-89E8F7E061B6

Q30969912-218D0B83-F74B-4980-BB98-E6D6D4DA27D4

Q30969912-29942958-0F86-4B51-9E87-28621A61547C

Q30969912-2DFEE4D7-97A5-4785-A3A0-1275ADE24079

Q30969912-355C68CC-3BCB-4F72-A60E-22BD9B18A5B0

Q30969912-4101E1D1-1AAC-42FF-8A49-347D4C52BF9D

Q30969912-41DCDCEB-3BCB-4806-8AB9-ACF779B7B6BC

Q30969912-4E1381E8-389E-4EB9-9E38-333A31CB2EAF

Q30969912-4F20BCCC-95DE-4797-9C9E-34DF97B3B9D4

P304

Q30969912-A2B4C082-06B6-459E-90D5-702CFC52B3EA

P31

Q30969912-FA8A016F-8824-4076-91CD-0424BEC231D2

P356

Q30969912-14F5BA26-F493-4C75-89B9-2928851B6D14

P433

Q30969912-01193538-BBD9-4855-AF0E-A9B233028DAC

P478

Q30969912-9BB04623-B23D-4A12-9221-8C55A4CFA18B

P50

Q30969912-2FEC373E-9582-490F-9302-7E98187943C1

Q30969912-33DCA886-E2A5-4286-89C7-4E0BF93695B9

Q30969912-75B0EA53-01F0-4A5B-A932-AF404DD28E7A

P577

Q30969912-E69092E3-075C-4DCA-AFF1-645C6BFB7DE0

P698

Q30969912-C513BACD-221E-465A-82CD-C68CABC948FC

P356

S1470-2045(15)70057-4

P1433

The Lancet Oncology

P1476

Response assessment criteria for brain metastases: proposal from the RANO group

@en

P2093

Brigitta G Baumert

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Daniel P Barboriak

http://www.w3.org/2001/XMLSchema#string

David R Macdonald

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

Eudocia Q Lee

http://www.w3.org/2001/XMLSchema#string

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

Gordon J Harris

http://www.w3.org/2001/XMLSchema#string

Hidefumi Aoyama

http://www.w3.org/2001/XMLSchema#string

Igor J Barani

http://www.w3.org/2001/XMLSchema#string

P304

e270-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(15)70057-4

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Martin J van den Bent

Elisabeth de Vries

P577

2015-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26065612

http://www.w3.org/2001/XMLSchema#string